Integra LifeSciences Holdings C (IART) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Integra LifeSciences Holdings C

NasdaqGS•Healthcare•Medical Devices

$13.63+0.02(<0.01%)Pre-market

Market Cap

$1.05B

P/E

80.9x

P/S

0.6x

P/B

1.0x

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

How this company scores

WeakMetricSide Score: 58/100

Grade capped at D — Interest coverage below 1× (0.8x) — earnings cannot cover interest. Strongest: Cash & Earnings Quality (19/25); weakest: Profitability (10/25).

Profitability10/25

Growth18/25

Balance Sheet & Red Flags11/25

Cash & Earnings Quality19/25

Strengths

Rising earningsCash-backed earningsProfit converts from growthConsistent growth

Grade capped at D

Interest coverage below 1× (0.8x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 80.9x5y range 20.9x – 95.4x

Currently above its 12-quarter median.

P/S · 0.6x5y range 0.4x – 3.8x

Currently below its 20-quarter median.

P/B · 1.0x5y range 0.7x – 3.4x

Currently below its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 4 of the last 8 quarters — earnings are not translating to cash.

Cash Burn

Watch

4 of the last 8 quarters had negative FCF — inconsistent cash generation raises sustainability concerns.

Price & Volume

Market Cap $1.05B

Metrics at a Glance

as of September 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $1.66B
Q. Revenue: $411.18M
TTM EBITDA: $302.97M
TTM Op. Income: $72.69M
Q. Op. Income: $18.90M
TTM Net Income: $13.01M
Q. Net Income: $14.85M
EPS: $0.19
Shares Out.: $77.39M

$1.66B in TTM revenue grew 0.8% YoY, reaching $411.18M last quarter. TTM EBITDA of $302.97M and TTM operating income of $72.69M show growth is flowing through to the bottom line. TTM net income of $13.01M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 3 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 51.0%
EBITDA Margin: 14.1%
Op. Margin: 4.6%
Net Margin: 3.6%

Op. margin of 4.6% is up 1.7% YoY — cost efficiency is improving. Net margin at 3.6% and gross margin of 51.0% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 57% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 80.9x
P/S Ratio: 0.6x
P/B Ratio: 1.0x

At 80.9x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 0.6x and P/B of 1.0x provide additional context. P/E sits above typical market levels while revenue growth is below 5%.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $3.51B
Cash: $252.26M
Long-Term Debt: $697.50M
Book Value: $1.07B
D/E Ratio: 0.7
Debt/EBITDA: 12.0

With $3.51B in assets and $697.50M in long-term debt, D/E is 0.7and book value is $1.07B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 5 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $95.98M
TTM Free Cash Flow: $85.78M
FCF Margin: 5.2%
FCF / Net Income: 6.6

TTM FCF of $85.78M on $95.98M in operating cash flow. The FCF / Net Income ratio of 6.6x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 3 consecutive quarters — an improving trend.